UNSPSC 51352301: Almestrone

This classification denotes a steroidal estrogen with the molecular formula C19H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N18A31MTB0, chemically known as 3-hydroxy-7alpha-methylestra-1,3,5(10)-trien-17-one but generally known as almestrone, which bears US NIH Compound Identifier 65601. European Medicines Agency schedules Almestrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05346MIG.

UNSPSC 51352301 Almestrone is a Commodity code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products for distribution across their facilities and programs. The work involves manufacturing and supplying identified pharmaceutical products with specific National Drug Codes (NDCs) and associated product data (SKUs, UPCs, generic descriptions, strength, dosage forms, packaging configurations, and manufacturing locations) to authorized wholesalers under cooperative purchasing agreements. Vendors must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three designated wholesalers with chargeback systems in place, and offer flexible pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus pricing. State and local purchasing offices and multistate cooperative purchasing alliances drive solicitations under this code, with vendors required to carry comprehensive insurance including $5,000,000 commercial general liability per occurrence and maintain product expiration dates of at least one year from manufacture with a minimum six-month shelf life.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The MMCAP solicitation (S1070000015802) covers participating state and local government facilities in Minnesota and Oregon, with awarded vendors to be provided to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026 and contracts effective July 1, 2026. Evaluation weighting prioritizes price competitiveness at 75 percent, with 10 percent on fixed pricing, 5 percent each on compliance with administrative fee data format and EDI capability, and 5 percent on agreement to a 3 percent administrative fee. The contract term runs two years for new responders with optional extensions, while incumbents' amendments extend through June 30, 2028. No specific award value or set-aside designations were disclosed; performance penalties range from $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines.